Lasmiditan is a medicinal product currently in clinical development for the acute treatment of migraine. A migraine is usually a moderate or severe headache felt as a throbbing pain on one side of the head. Many people also have symptoms such as nausea, vomiting and increased sensitivity to light or sound. Migraines may be with aura (specific warning signs just before the migraine begins, such as seeing flashing lights), although the most common type is without aura (no specific warning signs).
Lasmiditan presumably exerts its therapeutic action in the treatment of migraine through effects at a specific serotonin receptor called 5-HT1F; however, the precise mechanism is unknown. If licenced, lasmiditan will offer an additional option for first and/or second-line acute treatment of migraine with or without aura in adults.
Tofersen (BIIB067) is in clinical development for the treatment of amyotrophic lateral sclerosis (ALS – also known as motor neurone disease) caused by mutations in the SOD1 gene (SOD1-ALS). ALS is a progressive disease of the nervous system, where nerve cells in the brain and spinal cord that control voluntary movement gradually deteriorate, causing loss of muscle function and paralysis. ALS is a debilitating and life-threatening disease. The gradual loss of neurons leads to a paralysing effect on muscles used for breathing, which usually leads to death from respiratory failure.